Meeting
2021 Gastrointestinal Cancers Symposium
The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Authors
Kohei Shitara
National Cancer Center Hospital East, Kashiwa, Japan
Kohei Shitara , Ben George , Julien Taieb , Raghav Sundar , Marwan Fakih , Lukas Makris , Karim A. Benhadji , Michele Ghidini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT02500043
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 247)
DOI
10.1200/JCO.2021.39.3_suppl.247
Abstract #
247
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari
Poster
2022 ASCO Annual Meeting
Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent clostridioides difficile infection: Data from ECOSPOR III, a phase 3 randomized trial.
First Author: Alla Paskovaty
Poster
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
First Author: Andrew James Weickhardt
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari